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Foreword
As the largest organ o f the body, the skin performs multiple critical functions, such as 
serving as the primary barrier to the external environment. For this reason, the skin is 
often exposed to potentially hazardous agents, including chemicals, which may contrib­
ute to the onset o f a spectrum of adverse health effects ranging from localized damage 
(e.g., irritant contact dermatitis and corrosion) to induction o f im m une-m ediated re­
sponses (e.g., allergic contact dermatitis and pulmonary responses), or systemic toxicity 
(e.g., neurotoxicity and hepatoxicity). Understanding the hazards related to skin contact 
w ith chemicals is a critical component o f modern occupational safety and health pro­
grams.
In  2009, the National Institute for Occupational Safety and H ealth (N IO SH ) pub­
lished Current Intelligence Bulletin (CIB) 61: A  Strategy fo r  Assigning N ew  N IO S H  Skin 
Notations [N IO SH  2009-147]. This document provides the scientific rationale and 
framework for the assignment o f multiple hazard-specific skin notations (SK) that 
clearly distinguish between the systemic effects, direct (localized) effects, and immune- 
mediated responses caused by skin contact with chemicals. The key step within assign­
m ent o f the hazard-specific SK is the determination o f a substance’s hazard potential, or 
its potential for causing adverse health effects as a result o f skin exposure. This determ i­
nation entails a health hazard identification process that involves use o f the following:
• Scientific data on the physicochemical properties o f a chemical
• D ata on hum an exposures and health effects
• Empirical data from in vivo and in vitro laboratory testing
• Com putational techniques, including predictive algorithms and mathematical 
models that describe a selected process (e.g., skin permeation) by means of ana­
lytical or numerical methods.
This Skin N otation Profile provides the SK assignment and supportive data for ethylene 
glycol dinitrate (E G D N ; CAS No. 628-96-6). In  particular, this document evaluates 
and summarizes the literature describing the substance’s hazard potential and its assess­
m ent according to the scientific rationale and framework outlined in CIB 61. In  m eet­
ing this objective, this Skin N otation Profile intends to inform the audience— mostly 
occupational health practitioners, researchers, policy- and decision-makers, employers, 
and workers in potentially hazardous workplaces— so that improved risk-management 
practices may be developed to better protect workers from the risks o f skin contact with 
the chemical o f interest.
John Howard, M .D.
Director, National Institute for Occupational 
Safety and Health 
Centers for Disease Control and Prevention
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Abbreviations
A C G IH  American Conference o f Governm ental Industrial Hygienists
CIB Current Intelligence Bulletin
cm2 square centimeter(s)
cm/hr centimeter(s) per hour
DEREK™ Deductive Estim ation o f Risk from Existing Knowledge
D IR skin notation indicating the potential for direct effects to the skin 
following contact w ith a chemical
E C European Commission
E G D N ethylene glycol dinitrate
G H S Globally Harmonized System of Classification and Labeling o f Chemicals
IA R C International Agency for Research on Cancer




Kp o , coefficient in the protein fraction o f the stratum corneum
Kpsc permeation coefficient in the lipid fraction o f the stratum corneum
L D 50 dose resulting in 50% mortality in the exposed population
D L o dermal lethal dose
log KO W base-10 logarithm of a substance’s octanol-water partition
m 3 cubic meter(s)
mg milligram(s)
mg/cm 2 milligram(s) per square centimeter
mg/cm 2/h r milligram(s) per square centimeter per hour
m g/m 3 milligram(s) per cubic meter
mL milliliter(s)
M W molecular weight
N IO S H National Institute for Occupational Safety and Health
N T P National Toxicology Program
O E L occupational exposure limit
O SH A Occupational Safety and H ealth Administration
REL recommended exposure limit
RF retention factor
SEN skin notation indicating the potential for im m une-m ediated reactions 
following exposure o f the skin
SI ratio ratio o f skin dose to inhalation dose
SK skin notation
SW solubility
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SYS
USEPA
skin notation indicating the potential for systemic toxicity following 
exposure o f the skin 
United States Environmental Protection Agency
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Absorption—The transport o f a chemical from the outer surface o f the skin into both 
the skin and systemic circulation (including penetration, permeation, and resorption).
Acute exposure— Contact with a chemical that occurs once or for only a short period 
o f time.
Cancer—Any one o f a group o f diseases that occurs when cells in the body become 
abnormal and grow or multiply out o f control.
Contaminant—A  chemical that is (1) unintentionally present w ithin a neat substance 
or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen 
and present w ithin a neat substance or mixture at a concentration less than 0.1%.
Cutaneous (or percutaneous)— Referring to the skin (or through the skin).
Dermal— Referring to the skin.
Dermal contact— Contact with (touching) the skin.
Direct effects— Localized, non-im m une-m ediated adverse health effects on the skin, 
including corrosion, primary irritation, changes in skin pigmentation, and reduction/ 
disruption o f the skin barrier integrity, occurring at or near the point o f contact with 
chemicals.
Immune-mediated responses— Responses mediated by the immune system, including 
allergic responses.
Sensitization— A  specific im mune-mediated response that develops following expo­
sure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis 
(ACD) or other im m une-m ediated diseases such as asthma, depending on the site and 
route o f re-exposure.
Substance— A  chemical.
Systemic effects— Systemic toxicity associated with skin absorption o f chemicals after 
exposure o f the skin.
Glossary
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1 Introduction
1.1 General Substance Information
Chemical: Ethylene Glycol D initrate 
(E G D N )
CAS No: 628-96-6  
Molecular weight (MW): 152.06 









E G D N ; 1,2-Ethanediol dinitrate; E th ­
ylene dinitrate; Ethylene nitrate; Glycol 
dinitrate; Nitroglycol; E G N
Uses:
Ethylene glycol dinitrate (E G D N ) is used 
primarily in the production o f explosives 
[N IO SH  1978].
1.2 Purpose
This Skin Notation Profile presents (1) a 
brief summary o f technical data associat­
ed with skin contact with ethylene glycol 
dinitrate (E G D N ) and (2) the rationale 
behind the hazard-specific skin notation 
(SK) assignment for E G D N . The SK 
assignment is based on the scientific ra­
tionale and logic outlined in the Current 
Intelligence Bulletin (CIB) 61: A  Strategy 
fo r  Assigning N ew  N IO S H  Skin Notations 
[N IO SH  2009]. The summarized infor­
mation and health hazard assessment are 
limited to an evaluation o f the poten­
tial health effects o f dermal exposure to 
E G D N . A  literature search was conduct­
ed through July 2010 to identify informa­
tion on E G D N , including but not limited 
to data relating to its toxicokinetics, acute 
toxicity, repeated-dose systemic toxicity,
carcinogenicity, biological system/func­
tion-specific effects (including reproduc­
tive and developmental effects and immu- 
notoxicity), irritation, and sensitization. 
Inform ation was considered from studies 
of humans, animals, or appropriate m od­
eling systems that are relevant to assessing 
the effects o f dermal exposure to EG D N .
1.3 Overview of SK Assignment 
for EGDN
E G D N  is potentially capable o f causing 
systemic toxic effects following skin con­
tact. A  critical review of available data has 
resulted in the following SK assignment 
for E G D N : SK: SYS. Table 1 provides an 
overview of the critical effects and data 
used to develop the SK assignment for 
E G D N .







Table 1. Summary o f  the SK assignments for E G D N
Skin notation Critical effect Available data
SK: SYS Cardiovascular (Vasodilation; 
Fluctuations within blood pressure)
Limited human and animal data
2 Systemic Toxicity from Skin 
Exposure (SK: SYS)
Toxicokinetic studies following dermal ex­
posure to E G D N  were identified. In  vivo 
skin absorption studies indicated that ap­
proximately 3 milligrams (mg) of the sub­
stance (13.7%) of the dose applied under 
occlusive conditions to 1 square centime­
ter (cm2) o f the forearms was absorbed 
through the human skin during the 7-hour 
test period [Gross et al. 1960]. Hogstedt 
and Stahl [1980] reported that skin ab­
sorption was a major route o f entry o f the 
substance into the body when the hands 
o f human volunteers were exposed to dy­
namite vapors, or to the combination of 
vapors and the solid phase, with and w ith­
out gloves. These investigators stated that 
a substantial part o f 20 mg of E G D N  was 
absorbed through the hands after 2 hours. 
O ther studies provided evidence for der­
mal absorption o f E G D N  in humans. For 
example, the substance was reported to 
cause headache in humans when applied 
to the skin o f the forearms o f hum an vol­
unteers [Crandall et al. 1931]. Fukuchi 
[1981] reported that workers with unde­
tectable E G D N  in blood and urine sam­
ples prior to explosive production work 
had high levels o f the substance in the 
blood and urine after engaging in explo­
sive production. O ther in vivo studies in 
humans also indicated that E G D N  pen­
etrated the skin and into the body system 
through nylon and rubber gloves [E inert 
et al. 1963; Yoshikawa 1964]. W illiams
and M urray [1966] conducted an in vi­
tro kinetic analysis o f blood E G D N  con­
centration and reported that E G D N  is 
rapidly absorbed into hum an skin. Gross 
et al. [1960] also investigated the rate of 
dermal absorption o f E G D N  in rats un­
der occlusive conditions, by applying 100 
to 600 milligrams per square centimeter 
(mg/cm2) of the substance in a gelatinous 
mixture (containing 93% of the substance 
and 7% nitrocellulose) or 200 to 800 mg 
of the substance in an “explosive soft 
paste” (containing 22% of the substance, 
6.0% of dinitrotoluene, 5.0% trinitrotolu­
ene, 0.9% nitrocellulose, 1.0% sawdust, 
64.9% sodium chloride, and 0.2% iron 
oxide). These investigators reported that 
half o f the 100 mg of the gel containing 
93% of the substance was absorbed after 
1 day, and all of it was absorbed after 8 
days. The initial rate o f absorption was 
reported as approximately 10 milligrams 
per square centimeter per hour (mg/cm2/  
hour). However, the substance from the 
soft paste containing 22% E G D N  was 
absorbed more slowly, w ith an initial ab­
sorption rate of approximately 6.5 m g/ 
cm2/hour. These rates (i.e., 6.5-10 mg/ 
cm2/hour) were 3- to 4-fold higher than 
in volunteers [Gross et al. 1960]. O n  the 
basis of available data from toxicokinetic 
studies in humans and animals, it appears 
that E G D N  is absorbed through the skin 
following dermal exposure.
The potential of E G D N  to pose a skin ab­
sorption hazard was also evaluated with use 
o f a predictive algorithm for estimating and
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evaluating the health hazards of dermal ex­
posure to chemical substances [N IO SH  
2009]. The evaluation method compares 
an estimated chemical dose accumulated 
in the body from skin absorption and an 
estimated dose from respiratory absorption 
associated with a reference occupational 
exposure limit. O n the basis of this algo­
rithm, a ratio of the skin dose to the inhala­
tion dose (SI ratio) o f 39.45 was calculated 
for E G D N . An SI ratio o f >0.1 indicates 
that a chemical is capable of producing sys­
temic toxicity from skin exposure [N IO SH  
2009]. Additional information on the SI 
ratio and the variables used in its calcula­
tion are included in the appendix.
No dermal lethal dose (LD Lo) for humans 
or dermal L D 50 value (the dose resulting 
in 50% mortality in the exposed popula­
tion) has been identified for E G D N . Lack 
of adequate information on the acute 
dermal toxicity of E G D N  precludes any 
conclusion regarding the potential of the 
substance to be toxic following acute der­
mal exposure.
Studies investigating the health effects of 
E G D N  in humans were identified [Cran­
dall et al. 1931; E inert et al. 1963; H og- 
stedt and Axelson 1977]. Crandall et al. 
[1931] studied the development of toler­
ance to the vasodilating effects of E G D N  
and the duration of time required to de­
velop tolerance in hum an volunteers. Re­
sponse to E G D N  was determined based 
on the “headache dose” or the dose that 
caused a moderate headache within a sub­
ject. Doses ranging from 1.8 to 3.5 mil­
liliter (mL) o f a 1% solution o f E G D N  
in alcohol were applied to the skin of the 
forearm. The authors reported that tol­
erance to E G D N  occurred at 160 mg. 
The time required to develop tolerance 
to E G D N  following application of one 
“headache dose” ranged between 24 to
36 hours with an average duration of 32 
hours. The results o f this study provide ev­
idence o f dermal uptake of E G D N  and its 
ability to cause vasodilatation exhibited as 
within humans. Available epidemiological 
studies evaluated circulatory system ef­
fects of E G D N  in exposed workers who 
handled explosives containing E G D N  for 
1 to more than 20 years and developed 
chest pains or died suddenly after a brief 
period of withdrawal from exposure (e.g., 
a weekend) [Einert et al. 1963; H ogstedt 
and Axelson 1977]. The workers investi­
gated in both studies were likely exposed 
repeatedly through both inhalation and 
dermal contact. E inert et al. [1963] evalu­
ated 38 workers exposed to E G D N  and 
nitroglycerin during the manufacturing of 
dynamite. A ir and dermal samples were 
collected and coordinated with medical 
findings of evaluated workers. A lthough 
the effects of inhaling E G D N  could not 
be excluded, the authors reported that 
dermal uptake of E G D N  contributed 
greatly to the onset of the observed car­
diovascular effects including fluctuations 
with in pulse rate and decreases in blood 
pressure. H ogstedt and Axelson [1977] 
conducted a case-control study to investi­
gate the mortality rates w ithin workers ex­
posed to dynamite containing E G D N . A  
significant increase in ischemic heart dis­
ease was reported. The authors stated that 
the results of this study indicate excessive 
mortality caused by ischemic heart disease 
among workers with long-term  exposures 
to dynamite containing E G D N  and ni­
troglycerin. I t  appears from the studies of 
humans that repeated and prolonged der­
mal exposure to E G D N  may cause sys­
temic effects that focus on the cardiovas­
cular system, although the contribution of 
inhalation exposure or exposure to other 
materials is uncertain.







Table 2. Summary of the carcinogenic designations* for EG D N  by numerous 








Abbreviations: A C G IH  = American Conference of Governmental Industrial Hygienists; E C  = European Commission, Joint Re­
search, Institute for H ealth and Consum er Protection; IA R C  = International Agency for Research on Cancer; N IO S H  = National 
Institute for Occupational Safety and Health; N T P  = National Toxicology Program; USEPA = United States Environmental 
Protection Agency.
*Note: The listed cancer designations were based on data from nondermal (such as oral or inhalation) exposure rather than dermal 
exposure.
N IO S H  [1978] reviewed the hazards of 
occupational exposure to E G D N  and 
nitroglycerin. The results of the evalua­
tion revealed that E G D N  was capable of 
causing several adverse health effects in ­
cluding decreases in systolic, diastolic, and 
pulse pressures during initial exposure are 
suggestive o f vasodilation, and increases in 
diastolic pressure from the levels during 
initial exposure are indicative of compen­
satory vasoconstriction. Symptoms of ex­
posure include headaches, dizziness, nau­
sea, chest pains, and palpitations. N IO S H  
[1978] concluded that these effects can be 
readily produced by dermal exposures to 
E G D N  should be minimized due to the 
ability of the substance to be absorbed via 
the skin and contribute to systemic toxicity.
No repeat-dose studies in animals following 
dermal exposure to E G D N  were identi­
fied. No standard toxicity or specialty stud­
ies evaluating biological system /  function- 
specific effects (including reproductive and 
developmental effects and immunotoxic- 
ity) following dermal exposure to E G D N  
were identified.
No epidemiological studies that evaluated 
the potential of E G D N  to cause cancer 
in workers exposed to it or that evaluated 
the carcinogenicity potential o f E G D N  in 
animals following dermal exposure were 
identified. Table 2 provides a summary 
of carcinogenic designations for E G D N  
from multiple governmental and nongov­
ernmental organizations.
Taken together, data from the toxicokinet- 
ic studies in humans and animals [Gross 
et al. 1960; Fukuchi 1981*], data from hu­
man studies [Crandall et al. 1931; Einert 
et al. 1963; Hogstedt and Axelson 1977], 
supported by a mathematical model, dem ­
onstrate that E G D N  is absorbed through 
the skin and can cause systemic toxicity 
such as circulatory system effects. N IO S H  
[1978] stated that E G D N  was capable of 
causing decreased blood pressure, vasodi­
lation, headaches, dizziness, nausea, chest 
pains, and palpitations following dermal 
exposures. Therefore, on the basis of the
References in bold text indicate studies that served 
as the basis of the SK assignment.
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data for this assessment, E G D N  is assigned 
the SK: SYS notation.
3 Direct Effects on Skin (SK: DIR)
No data on corrosivity of E G D N  or from 
in vitro tests for corrosivity in hum an or 
animal skin models or integrity of cadav­
er skin were identified. No inform ation 
from occupational exposure experience is 
available to suggest tha t E G D N  is a skin 
irritant. A  skin irritation test conducted 
by Kanerva et al. [1991] on 20 persons 
indicated concentrations of 0.1% to 0.5% 
E G D N  did not cause a skin irritation 
for any o f the test subjects. No data from 
animal studies was found to suggest that 
the substance is a skin irritant. The struc- 
ture-activity relationship model, D educ­
tive Estim ation of Risk from Existing 
Knowledge (D ER EK TM) for W indows, 
predicted E G D N  to be negative for skin 
irritation. Tests conducted on humans and 
animals provided no evidence that E G D N  
is a skin irritant. Therefore, on the basis of 
the data for this assessment, E G D N  is not 
assigned the SK: D IR  notation.
4 Immune-mediated 
Responses(SK: SEN)
There is limited information available for 
determining whether E G D N  is a skin sen­
sitizer. Kanerva et al. [1991] has provided 
an occupational case report o f allergic skin 
reactions. According to this case report, 
four workers who handled explosives and 
developed allergic contact dermatitis were 
patch-tested with a series o f dilutions of 
the chemicals in the explosives. O ne of 
two subjects patch-tested with 0.1 to 2% 
E G D N  in aqueous solution had positive 
allergic reactions to the substance at the 
dilutions tested, whereas the other was
negative at all the dilutions. No standard 
studies of the skin sensitization potential 
of E G D N  in humans or animals were 
identified. D E R E K  predicted E G D N  to 
be negative for skin sensitization. Because 
insufficient data are available for this as­
sessment, E G D N  is not assigned the SK: 
SEN notation.
5 Summary
D ata from the toxicokinetic studies in 
humans and animals [Gross et al. 1960; 
Fukuchi 1981] demonstrate that E G D N  
is absorbed through the skin following 
dermal exposure. A lthough no acute, re- 
peat-dose, subchronic, or chronic dermal 
toxicity studies in animals were identi­
fied, hum an studies [Crandall et al. 1931; 
Einert et al. 1963; Hogstedt and Axelson 
1977] showed systemic toxicity such as 
cardiovascular system effects. However, 
those reports provide limited data that 
preclude a confident estimate o f the toxic­
ity from dermal exposure. N IO S H  [1978] 
stated that E G D N  was capable of caus­
ing decreased blood pressure, vasodila­
tion, headaches, dizziness, nausea, chest 
pains, and palpitations following dermal 
exposures. Limited data were noted that 
showed the substance is not a skin irritant 
in humans. The data were judged insuffi­
cient for assigning a skin sensitization no­
tation for the substance because only one 
nonstandard study indicated that E G D N  
is a skin sensitizer. Therefore, on the basis 
of these assessments, E G D N  is assigned a 
composite skin notation o f SK: SYS.
Table 3 summarizes the skin hazard des­
ignations for E G D N  previously issued 
by N IO S H  and other organizations. The 
equivalent dermal designation for E G D N , 
according to the Globally Harmonized Sys­
tem  (G HS) of Classification and Labeling







Table 3. Summary o f the previously issued skin hazard designations for E G D N
Organization Skin hazard designation
NIOSH [2005] [skin]: Potential for dermal absorption
OSHA [2009] [skin]: Based on potential contribution to the overall exposure by the cuta­
neous route, including the mucous membranes and the eyes, either by air­
borne particles or, more particularly, by direct contact with the substance
ACGIH [2001] [skin]: Based on the available data, demonstrating systemic toxicity following 
absorption through intact skin with considerable ease
EC [2010] R27: Very toxic in contact with skin
Abbreviations: A C G IH  = American Conference of Governmental Industrial Hygienists; E C  = European Commission, Joint Re­
search, Institute for H ealth and Consum er Protection; N IO S H  = National Institute for Occupational Safety and Health; O S H A  = 
Occupational Safety and H ealth Administration.
of Chemicals, is Acute Toxicity Category 
1 (Hazard statement: Fatal in contact with 
the skin) [European Parliament 2008].
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Appendix: Calculation of the SI Ratio for EGDN
This appendix presents an overview of the 
SI ratio and a summary of the calculation 
o f the SI ratio for E G D N . Although the 
SI ratio is considered in the determination 
o f a substance’s hazard potential following 
skin contact, it is intended only to serve as 
supportive data during the assignment of 
the N IO S H  SK. A n in-depth discussion 
on the rationale and calculation of the SI 
ratio can be found in Appendix B o f the 
Current Intelligence Bulletin (CIB) 61: A  
Strategy fo r  Assigning N ew  N IO S H  Skin 
Notations [N IO SH  2009].
Overview
The SI ratio is a predictive algorithm for 
estimating and evaluating the health haz­
ards of skin exposure to substances. The 
algorithm is designed to evaluate the po­
tential for a substance to penetrate the 
skin and induce systemic toxicity [N IO SH  
2009]. The goals for incorporating this al­
gorithm into the proposed strategy for as­
signing the SYS notation are as follows:
(1) Provide an alternative method to 
evaluate substances for which no 
clinical reports or animal toxicity 
studies exist or for which empirical 
data are insufficient to determine 
systemic effects.
(2) Use the algorithm evaluation re­
sults to determine whether a sub­
stance poses a skin absorption haz­
ard and should be labeled with the 
SYS notation.
The algorithm evaluation includes three 
steps: (1) determining a skin permeation 
coefficient (Kp ) for the substance of in ­
terest, (2) estimating substance uptake by
the skin and respiratory absorption routes, 
and (3) evaluating whether the substance 
poses a skin exposure hazard.
The algorithm is flexible in the data re­
quirement and can operate entirely on the 
basis o f the physicochemical properties 
of a substance and the relevant exposure 
parameters. Thus, the algorithm is inde­
pendent o f the need for biologic data. A l­
ternatively, it can function with both the 
physicochemical properties and the ex­
perimentally determined permeation co­
efficient when such data are available and 
appropriate for use.
The first step in the evaluation is to deter­
mine the Kp for the substance to describe 
the transdermal penetration rate of the 
substance [N IO SH  2009]. The Kp, which 
represents the overall diffusion o f the sub­
stance through the stratum corneum and 
into the blood capillaries of the dermis, is 
estimated from the com pound’s molecular 
weight (M W ) and base-10 logarithm of 
its octanol-water partition coefficient (log 
KOW). In  this example, Kp is determined 
for a substance with use o f Equation 1. A 
self-consistent set o f units must be used, 
such as centimeters per hour (cm/hr), out­
lined in Table A1. O ther model-based es­
timates o f Kp may also be used [N IO SH  
2009].
Equation 1: Calculation of Skin Permeation 
Coefficient (Kp)
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where Kpsc  is the permeation coefficient in 
the lipid fraction o f the stratum corneum, 
kpol is the coefficient in the protein frac­
tion o f the stratum corneum, and K a q  is 
the coefficient in the watery epidermal 
layer. These components are individually 
estimated by
log Kp sC = -1.326 + 0.6097 x log KqW - 
0.1786 x M W 0.5
Kp o l = 0.0001519 x M W -0.5
K = 2.5 x M W -0.5aq
The second step is to calculate the bio­
logic mass uptake o f the substance from 
skin absorption (skin dose) and inhalation 
(inhalation dose) during the same period 
o f exposure. The skin dose is calculated 
as a mathematical product o f the Kp , the 
water solubility (SW) o f the substance, the 
exposed skin surface area, and the dura­
tion o f exposure. Its units are milligrams 
(mg). Assume that the skin exposure con­
tinues for 8 hours to unprotected skin on 
the palms o f both hands (a surface area of 
360 cm 2 ).
Equation 2: Determination of Skin Dose
Skin dose = Kp  x Sw x Exposed skin surface 
area x Exposure time
= Kp (cm/hr) x Sw (mg/cm 3 ) x 
360 cm 2  x 8 hours
The inhalation dose (in mg) is derived on 
the basis of the occupational exposure limit 
(OEL) of the substance—if the O E L  is de­
veloped to prevent the occurrence of systemic 
effects rather than sensory/irritant effects or 
direct effects on the respiratory tract. Assume 
a continuous exposure of 8 hours, an inhala­
tion volume of 10 cubic meters (m3) inhaled 
air in 8 hours, and a factor of 75% for reten­
tion of the airborne substance in the lungs 
during respiration (retention factor, or RF).
Equation 3: Determination of Inhalation Dose
Inhalation dose = O E L  x Inhalation 
volume x R F
= O E L  (m g/m 3) x 10 m3 
x 0.75
The final step is to compare the calculated 
skin and inhalation doses and to present 
the result as a ratio o f skin dose to inhala­
tion dose (the SI ratio). This ratio quan­
titatively indicates (1) the significance of 
dermal absorption as a route o f occupa­
tional exposure to the substance and (2) 
the contribution of dermal uptake to sys­
temic toxicity. I f  a substance has an SI ra­
tio greater than or equal to 0.1, it is con­
sidered a skin absorption hazard.
Calculation
Table A1 summarizes the data applied in 
the previously described equations to de­
termine the SI ratio for E G D N . The cal­
culated SI ratio was 39.45. O n  the basis of 
these results, E G D N  is predicted to rep­
resent a skin absorption hazard.
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Table A1. Summary o f data used to calculate the SI ratio for E G D N
Variables used in calculation Units Value
Skin permeation coefficient
Permeation coefficient of stratum corneum lipid path(Kp sc) cm/hr 0.00151
Permeation coefficient of the protein fraction of the stratum
corneum (Kpol) cm/hr 1.23183 x 10-5
Permeation coefficient of the watery epidermal layer (Kaq) cm/hr 0.20274
Molecular weight (MW)* amu 152
Base-10 logarithm of its octanol-water partition coefficient
(Log Kow)* None 1.16
Calculated skin permeation coefficient (Kp) cm/hr 0.00151
Skin dose
Water solubility (SW )* mg/cm3 6.8
Calculated skin permeation coefficient (Kp) cm/hr 0.00151
Estimated skin surface area (palms of hand) cm2 360
Exposure time hr 8
Calculated skin dose mg 29.58
Inhalation Dose
Occupational exposure limit (OEL)^ mg/m3 0.1
Inhalation volume m3 10
Retention factor (RF) None 0.75
Inhalation dose mg 0.75
Skin dose-to-inhalation dose (SI) ratio None 39.45
^Variables identified from SRC [2009].
+The O E L  used in calculation of the SI ratio was the N IO SH -recom m ended exposure lim it (REL) [N IO S H  2005].
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